With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. This evidence concerns the gene ACVR1 and fibrodysplasia ossificans progressiva.